文献速递甲状腺疾病

Graves病与毒性结节性甲状腺肿伴甲状腺功能亢进病程加重与阿尔茨海默病及血管性痴呆相关:基于两个大型队列的登记系统长期随访

Graves' Disease and Toxic Nodular Goiter, Aggravated by Duration of Hyperthyroidism, Are Associated with Alzheimer's and Vascular Dementia: A Registry-Based Long-Term Follow-Up of Two Large Cohorts.
PubMed 文献 · Thyroid · 2020-03-03

基于丹麦国家患者登记(DNPR)队列56,128例甲亢患者与224,512例匹配对照,及OPENTHYRO登记队列2,688例甲亢患者与10,752例甲状腺功能正常对照,中位随访约7年。DNPR队列甲亢患者痴呆风险升高(HR 1.17;95%CI 1.12-1.23),OPENTHYRO队列未达显著(HR 1.06;95%CI 0.89-1.26)。TSH每降低6个月,全因痴呆风险升高(HR 1.16;95%CI 1.12-1.22)。

要点

  • DNPR队列甲亢患者痴呆风险较对照升高(HR 1.17;95%CI 1.12-1.23)。
  • OPENTHYRO队列甲亢与痴呆风险无显著关联(HR 1.06;95%CI 0.89-1.26)。
  • TSH每降低6个月,全因痴呆风险升高(HR 1.16;95%CI 1.12-1.22)。

核心结论

  • 基于大规模登记数据,甲亢个体痴呆风险增加。
  • TSH每降低6个月,全因痴呆风险较TSH正常者升高16%。
  • 数据支持对甲亢患者进行早期诊断和干预。

研究设计与样本

  • 研究基于两个队列及匹配参考人群评估甲亢个体痴呆风险。
  • DNPR队列为丹麦全国登记队列,随访中位7.2年(1995年至2013年)。
  • OPENTHYRO登记队列包含235,547例在1995年至2011年间至少检测一次血清TSH的个体,随访中位7.3年。
  • 每个甲亢病例按年龄和性别采用密度抽样匹配4名对照。
  • 甲亢定义为ICD-10诊断毒性结节性甲状腺肿或Graves病,或DNPR与OPENTHYRO队列中分别两次TSH低于0.3 mU/L。

主要发现

  • DNPR队列有56,128例甲亢患者,其中2,689例登记痴呆;参考人群224,512例中10,199例痴呆(HR 1.17;95%CI 1.12-1.23)。
  • Graves病和毒性结节性甲状腺肿患者中阿尔茨海默病或血管性痴呆风险均较高。
  • OPENTHYRO队列有2,688例甲亢个体和10,752例甲状腺功能正常对照,其后分别有190例和473例诊断为痴呆(HR 1.06;95%CI 0.89-1.26)。
  • TSH每降低6个月,全因痴呆风险显著升高(HR 1.16;95%CI 1.12-1.22)。

临床怎么用

  • 作者认为数据支持对甲亢患者进行早期诊断和干预。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Dementia is an increasing burden to the health care system. It is currently debated whether hyperthyroidism is associated with a risk of dementia. Our aim was to determine the risk of dementia in hyperthyroid individuals and whether this was associated with duration of hyperthyroidism. Methods: Risk of dementia in hyperthyroid individuals was evaluated in two cohorts and matched reference populations. The Danish National Patient Registry (DNPR) cohort is a registry-based Danish nationwide cohort followed for a median of 7.2 years (from 1995 to 2013), whereas the OPENTHYRO registry cohort comprises 235,547 individuals who had at least one serum thyrotropin (TSH) measurement in the period from 1995 to 2011 and was followed for a median of 7.3 years. Each hyperthyroid case was matched with four controls according to age and sex using density sampling. Hyperthyroidism was defined as either an International Classification of Diseases Version 10 (ICD-10) diagnosis of toxic nodular goiter (TNG) or Graves' disease (GD), or two measurements of a TSH below 0.3 mU/L in the DNPR and OPENTHYRO registry cohort, respectively. The primary outcome was all-cause dementia, defined as either an ICD-10 code of dementia or prescription of medicine for dementia, with subgroup analyses of vascular dementia and Alzheimer's disease. Results: The DNPR cohort had 56,128 patients with hyperthyroidism, 2689 of whom were registered with dementia. The reference population had 224,512 individuals, of whom 10,199 had dementia (hazard ratio 1.17; 95% confidence interval [CI]: 1.12-1.23). Risk of dementia, whether Alzheimer's or vascular, was higher in both GD and TNG. The OPENTHYRO registry cohort constituted 2688 hyperthyroid individuals and 10,752 euthyroid control individuals of whom 190 and 473 individuals, respectively, were subsequently diagnosed with dementia (HR 1.06; 95% CI: 0.89-1.26). For each 6 months of decreased TSH, the risk of all-cause dementia was significantly higher (HR 1.16; 95% CI: 1.12-1.22). Conclusions: Using large-scale registry-based data, we found increased risk of dementia in hyperthyroid individuals. Every 6 months of decreased TSH was associated with increased risk of dementia by 16%, compared with individuals with normal TSH. Our data support early diagnosis and intervention in patients with hyperthyroidism.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Folkestad L, Brandt F, Lillevang-Johansen M, et al. Graves' Disease and Toxic Nodular Goiter, Aggravated by Duration of Hyperthyroidism, Are Associated with Alzheimer's and Vascular Dementia: A Registry-Based Long-Term Follow-Up of Two Large Cohorts. Thyroid. 2020. PMID: 31984866. doi:10.1089/thy.2019.0672

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。